Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 9 No 2 (2024): December

Modulation of p53 and p21 Genes Expression in Cardiovascular Cultured Cells
Modulasi Ekspresi Gen p53 dan p21 dalam Sel Kultur Kardiovaskular



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.9135
Published
June 13, 2024

Abstract

This study explores the role of the p53 and p21 genes, central to the cell cycle arrest pathway, in cardiovascular diseases, focusing on their modulation by endocannabinoid ligands. Previous research has established the significance of CNR1 in cardiovascular regulation; however, its interaction with p53 pathways remains underexplored. We aimed to investigate the effects of Anandamide and Rimbonant on the expression levels of p53 and p21 in smooth muscle cells at both mRNA and protein levels. Our results indicate that Anandamide significantly increases p53 mRNA (3.191±0.38, Pv≤0.01) and protein (31.37±2.60) levels, while Rimbonant shows a decrease after 1 hour of treatment. Similarly, p21 expression was upregulated by Anandamide and downregulated by Rimbonant. These findings suggest that manipulating p53 activity through CNR1 ligands could potentially mitigate cardiovascular disease risks, warranting further investigation into their pharmacological applications.

Highlights:

  • Gene Modulation: Anandamide boosts p53 and p21 expression.
  • Rimbonant Effects: Rimbonant reduces these gene levels.
  • Therapeutic Potential: Indicates possibilities for cardiovascular disease treatment.

Keywords: P53 Gene, Cardiovascular Disease, Endocannabinoids, Anandamide, Rimbonant

References

  1. T.-J. Ai, J.-Y. Sun, L.-J. Du, C. Shi, C. Li, X.-N. Sun, Y. Liu, L. Li, Z. Xia, and L. Jia, "Inhibition of Neddylation by MLN4924 Improves Neointimal Hyperplasia and Promotes Apoptosis of Vascular Smooth Muscle Cells Through p53 and p62," Cell Death & Differentiation, vol. 25, pp. 319-329, 2018.
  2. Z. A. H. Alebady, O. A. Hatem, T. Abd Al-Hamza, F. M. Sarhan, and M. M. Raham, "P53/P21 Expression Increment as Predisposing Factor for Cancer Development in Hypertensive Patients in Al-Diwaniyah Province, Iraq," Hypertension, vol. 53, pp. 21, 2023.
  3. S. Azar, S. Udi, A. Drori, R. Hadar, A. Nemirovski, K. V. Vemuri, M. Miller, D. Sherill-Rofe, Y. Arad, and D. Gur-Wahnon, "Reversal of Diet-Induced Hepatic Steatosis by Peripheral CB1 Receptor Blockade in Mice is p53/miRNA-22/SIRT1/PPARα Dependent," Molecular Metabolism, vol. 42, no. 101087, 2020.
  4. S. Bátkai, Z. Járai, J. A. Wagner, S. K. Goparaju, K. Varga, J. Liu, L. Wang, F. Mirshahi, A. D. Khanolkar, and A. Makriyannis, "Endocannabinoids Acting at Vascular CB1 Receptors Mediate the Vasodilated State in Advanced Liver Cirrhosis," Nature Medicine, vol. 7, pp. 827-832, 2001.
  5. R. Beckerman and C. Prives, "Transcriptional Regulation by p53," Cold Spring Harbor Perspectives in Biology, vol. 2, no. a000935, 2010.
  6. G. H.-H. Chan, E. Chan, C. T.-K. Kwok, G. P.-H. Leung, S. M.-Y. Lee, and S.-W. Seto, "The Role of p53 in the Alternation of Vascular Functions," Frontiers in Pharmacology, vol. 13, no. 981152, 2022.
  7. J. Chayapong, H. Madhyastha, R. Madhyastha, Q. I. Nurrahmah, Y. Nakajima, N. Choijookhuu, Y. Hishikawa, and M. Maruyama, "Arsenic Trioxide Induces ROS Activity and DNA Damage, Leading to G0/G1 Extension in Skin Fibroblasts Through the ATM-ATR-Associated Chk Pathway," Environmental Science and Pollution Research, vol. 24, pp. 5316-5325, 2017.
  8. A. J. Donato, R. G. Morgan, A. E. Walker, and L. A. Lesniewski, "Cellular and Molecular Biology of Aging Endothelial Cells," Journal of Molecular and Cellular Cardiology, vol. 89, pp. 122-135, 2015.
  9. E. J. Downer, A. Gowran, Á. C. Murphy, and V. A. Campbell, "The Tumour Suppressor Protein, p53, Is Involved in the Activation of the Apoptotic Cascade by Δ9-Tetrahydrocannabinol in Cultured Cortical Neurons," European Journal of Pharmacology, vol. 564, pp. 57-65, 2007.
  10. W. S. El-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein, "WAF1, a Potential Mediator of p53 Tumor Suppression," Cell, vol. 75, pp. 817-825, 1993.
  11. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge, "The p21 Cdk-Interacting Protein Cip1 is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," Cell, vol. 75, pp. 805-816, 1993.
  12. W. S. Ho and M. E. Kelly, "Cannabinoids in the Cardiovascular System," Advances in Pharmacology, vol. 80, pp. 329-366, 2017.
  13. C. Ihling, J. Haendeler, G. Menzel, R. D. Hess, G. Fraedrich, H. E. Schaefer, and A. M. Zeiher, "Co-Expression of p53 and MDM2 in Human Atherosclerosis: Implications for the Regulation of Cellularity of Atherosclerotic Lesions," The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, vol. 185, pp. 303-312, 1998.
  14. A. Jerafi-Vider, I. Bassi, N. Moshe, Y. Tevet, G. Hen, and D. Splittstoesser, "VEGFC/FLT4-Induced Cell-Cycle Arrest Mediates Sprouting and Differentiation of Venous and Lymphatic Endothelial Cells," Cell Reports, vol. 35, 2021.

Downloads

Download data is not yet available.